Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

Fig. 3

Correlation of 6-month PFS with OS. Correlation in (a) all RCTs, (b) RCTs published before 2012 (1974–2012), and (c) RCTs published after 2012 (2013–2017). Abbreviations: HR hazard ratio, m month, OR odds ratio, OS overall survival, 6mPFS 6-month progression-free survival, RCT randomized control trial

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us